Azenta, Inc. (AZTA) Q4 2025 10-Q Quarterly Report
Azenta, Inc. (AZTA) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 5, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Azenta, Inc. Q4 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $148.6M, up 0.8% YoY; Sample Management Solutions $81.4M up 0.4%, Multiomics $67.2M up 1.4%
- • Operating margin Sample Management 4.6% vs 5.0% YoY, Multiomics -7.5% vs -4.8%, total company -0.9% vs 0.6%
- • Best segment Sample Management Solutions adjusted margin 6.1% vs 5.9%; worst Multiomics adjusted margin -6.5% vs -3.5%
- • Gross margin total 42.9% vs 46.7% YoY; Sample Management 43.9% vs 48.2%, Multiomics 41.5% vs 44.8%
- • Selling, general & admin expenses $60.6M, down $9.4M YoY mainly from lower compensation and one-time costs
Risk Factors
- • No new or materially updated risk factors disclosed this quarter compared to 2025 10-K
- • Continued risk of intellectual property disputes impacting proprietary technology and trademarks
- • Dependence on accuracy of third-party industry data and assumptions introduces uncertainty to market forecasts
- • Market position and opportunity assessments subject to high degree of risk and changing industry conditions
- • No specific financial risks such as liquidity or debt maturity changes detailed in this filing
Get deeper insights on Azenta, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.